• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Mod­er­na piv­ots from a buy­out to a plat­form tech al­liance as its strug­gling part­ner scores an­oth­er mar­quee al­ly

3 years ago
Deals

Fate and J&J end deal that once promised $3B in mile­stones; biotech cuts staff

3 years ago
Deals
Pharma

On in vi­vo cell ther­a­py quest, Take­da-backed En­so­ma buys a CRISPR up­start and bags $85M

3 years ago
Financing
Deals

On­ly 1 of 25 can­cer drug de­vel­op­ers fair­ly in­clud­ed mi­nor­i­ty pa­tients over five-year win­dow, BMJ analy­sis finds

3 years ago
R&D

In­tel­lia plots piv­otal tri­als for lead pro­grams as it lays out key ob­jec­tives

3 years ago
Pharma
Cell/Gene Tx

Af­ter an EU ap­proval, As­traZeneca and Sanofi's RSV an­ti­body seeks an FDA thumbs-up in Q3

3 years ago
R&D

Bausch + Lomb tack­les glau­co­ma aware­ness and re­search fund­ing with non­prof­it part­ner in new cam­paign

3 years ago
Pharma
Marketing

Ready for take­off: J&J's con­sumer health unit Ken­vue files for of­fi­cial sep­a­ra­tion

3 years ago
Pharma

Man­u­fac­tur­ing roundup: Lotte nabs BMS fa­cil­i­ty in New York; Al­ca­mi ac­qui­si­tion com­plete

3 years ago
Manufacturing

Sarep­ta march­es for­ward with its po­ten­tial DMD gene ther­a­py and an ex­pand­ed Catal­ent man­u­fac­tur­ing deal

3 years ago
Pharma
Manufacturing

Take­da touts in­ter­im PhI­II da­ta of en­zyme re­place­ment ther­a­py for rare blood dis­ease

3 years ago
R&D

Y-mAbs cuts 35% of staff; Genen­tech re-ups Nim­ble deal; Lan­dos shifts fo­cus; and more

3 years ago
News Briefing

The C-suite shuf­fle: On­copep­tides, Zymeworks re­place ex­ecs to start 2023

3 years ago
People

Am­gen kicks off 2023 deal­mak­ing with busy ADC up­start Synaf­fix

3 years ago
Financing
Deals

Chris Viehbach­er once again sets out to re­vamp R&D at a ma­jor bio­phar­ma. The last try led to his ouster

3 years ago
People
Bioregnum

WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in bil­lions lost from US un­ver­i­fied list

3 years ago
Financing
Deals

Klick Group hires McK­in­sey life sci­ence com­mer­cial­iza­tion chief to amp of­fer­ings

3 years ago
Pharma
Marketing

Gink­go joins Es­per­ovax to at­tempt RNA can­cer treat­ment — in a pill

3 years ago
Deals
R&D

Carmell Ther­a­peu­tics plans SPAC deal with Al­pha Health­care, by­pass­ing IPO

3 years ago
Deals

On the road to hu­man stud­ies, next-gen gene edit­ing con­tender Metageno­mi hauls in an ex­tra $100M

3 years ago
Deals

While keep­ing eye on snap NASH OK, In­ven­ti­va tests out al­ter­na­tive PhI­II path

3 years ago
R&D
FDA+

High­T­ide Ther­a­peu­tics rides NASH R&D wave with a $107M raise

3 years ago
Financing
Startups

Sanofi ex­pects Zan­tac ar­bi­tra­tion case with Boehringer In­gel­heim to be re­solved ear­ly this year

3 years ago
Pharma
Law

Pfiz­er leads top-sell­ing phar­ma fore­cast — Eval­u­ate re­port

3 years ago
R&D
Pharma
First page Previous page 395396397398399400401 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.